ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$12.28
0.10 (0.82%)
▲
5d:
-9.97%
30d:
-6.62%
90d:
+88.06%
HOLD
MODERATE Confidence
Analysis Updated: Nov 4, 2026 12:00 AM ET
Earnings: Nov 09, 2026
3d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Nov 4, 2026 at $12.20 · last confirmed Nov 4, 2026
Strength: 6.1/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $12.28, which is considered fair relative to its 30-day fair value range of $11.79 to $13.63.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $11.05, while resistance sits at $13.86.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.17 (+39.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $11.05, while resistance sits at $13.86.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.17 (+39.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.79 -
$13.63
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.8% below Wall St target ($17.17)
- NEUTRAL: Bottoming setup forming (49/100) — watch for confirmation
- CAUTION: 5-day price weakness (-10.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$11.79 -
$13.63
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$11.05
Resistance Level
$13.86
Current Trend
Strong Uptrend
Technical data as of
Nov 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.10
Wall Street Target
$17.17
(+39.8%)
Revenue Growth (YoY)
-76.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-248.8%
Share & Embed Analysis
Last updated: November 04, 2026 8:39 PM ET
Data refreshes hourly during market hours. Next update: 9:39 PM
Data refreshes hourly during market hours. Next update: 9:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
23 analysts |
$107 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 42 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$685 | 42 HOLD |
|
RCUS
Arcus Biosciences Inc |
STRONG BUY
15 analysts |
$41 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 57 HOLD |
